YANKCOM Partnership’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.44M Buy
2,031
+693
+52% +$708K 0.87% 23
2026
Q1
$1.23M Sell
1,338
-24
-2% -$24.3K 0.51% 48
2025
Q4
$1.46M Buy
1,362
+434
+47% +$415K 0.62% 39
2025
Q3
$708K Buy
928
+34
+4% +$25.3K 0.32% 78
2025
Q2
$697K Buy
894
+5
+0.6% +$3.88K 0.34% 76
2025
Q1
$734K Sell
889
-36
-4% -$30K 0.4% 69
2024
Q4
$714K Buy
+925
New +$766K 0.38% 75

Other funds holding LLY

YANKCOM Partnership's LLY Position: Q2 2026 in Review

YANKCOM Partnership increased its Eli Lilly (LLY) stake by 52% in Q2 2026, buying an estimated $708K and bringing the position to 2,031 shares worth $2.44M. The position accounts for 0.87% of the portfolio, ranked #23.

YANKCOM Partnership first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 1,856 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • YANKCOM Partnership held 2,031 shares of Eli Lilly worth $2.44M as of Q2 2026.
  • YANKCOM Partnership bought 693 Eli Lilly shares in Q2 2026, an estimated $708K.
  • Eli Lilly made up 0.87% of YANKCOM Partnership's portfolio in Q2 2026, its #23 holding.
  • YANKCOM Partnership first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 1,856 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on YANKCOM Partnership's 13F filing for Q2 2026, filed 21 Jul 2026.